<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743727</url>
  </required_header>
  <id_info>
    <org_study_id>LDV SOF T 2018</org_study_id>
    <nct_id>NCT03743727</nct_id>
  </id_info>
  <brief_title>Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/Sofosbuvir</brief_title>
  <official_title>The Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yassin Abdelghaffar Charity Center for Liver Disease and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yassin Abdelghaffar Charity Center for Liver Disease and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, uncontrolled study of twenty-five chronic HCV infected patients carried out
      at Yassin Abdel Ghaffar Charity Center for Liver Disease and Research. The aim of this study
      is to investigate the safety &amp; efficacy of combined therapy ledipasvir (LDV) and sofosbuvir
      (SOF) for treating HCV Genotype 4 in children aged 8 to 18. Due to previous positive results
      in other clinical studies of this drug it is expected that the drug will have high safety and
      high efficacy. Safety will be measured by checking for adverse effects, while efficacy will
      be measured by Real-Time Quantitative Polymerase Chain Reaction (qPCR) detecting viral
      nucleic acids in blood samples.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>During the 12 weeks of treatment.</time_frame>
    <description>The presence of any adverse effects will be used to characterize this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained Viral Clearance</measure>
    <time_frame>At Week 12 after end of treatment.</time_frame>
    <description>HCV RNA qPCR will be used to determine if the target of viral clearance has been established. Detection limit of the kit is 12 IU/ml.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hepatitis C Genotype 4</condition>
  <arm_group>
    <arm_group_label>Combined Therapy LDV and SOF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined therapy LDV and SOF</intervention_name>
    <description>All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).</description>
    <arm_group_label>Combined Therapy LDV and SOF</arm_group_label>
    <other_name>ledipasvir and sofosbuvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV chronic infection

          -  Treatment naive and treatment experienced (previous interferon treatment)

          -  No cirrhosis or compensated cirrhosis

        Exclusion Criteria:

          -  Co-infection with Hepatitis B (HBV)

          -  Other associated chronic liver illness

          -  Patients with history of hematemesis (non-cirrhotic portal hypertension)

          -  Patients with decompensated cirrhosis (as indicated by biopsy, fibroscan)

          -  Patients on drugs known to interact unfavorably (Amioidarone, ..)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawhida Y. Abdel Ghaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yassin Abdel Ghaffar Charity Center for Liver Disease and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mamdouh A. Ahmed</last_name>
    <phone>02-01221707770</phone>
    <email>dr.yassinabdelghaffar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Professor Yassin Abdel Ghaffar Charity Center for Liver Disease and Research</name>
      <address>
        <city>Nasr City</city>
        <state>Cairo</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamdouh A. Ahmed</last_name>
      <phone>02-01221707770</phone>
      <email>dr.yassinabdelghaffar@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yassin Abdelghaffar Charity Center for Liver Disease and Research</investigator_affiliation>
    <investigator_full_name>Dr. Tawhida Yassin Abdel Ghaffar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

